LLYHIGH SIGNALFINANCIAL10-K

Eli Lilly delivered substantially higher revenue and profitability driven by strong product portfolio performance, while significantly expanding its balance sheet and operational capacity.

The company's financial performance reflects robust demand across its pharmaceutical portfolio, with particularly strong momentum in key therapeutic areas. The substantial increase in inventory and accounts receivable suggests LLY is scaling operations to meet growing demand, while the expansion in stockholders' equity demonstrates strong capital generation and retention.

Comparing 2026-02-12 vs 2025-02-19View on EDGAR →
FINANCIAL ANALYSIS

LLY's financial profile expanded meaningfully across all major metrics, with revenue growing substantially to $65.2B and net income roughly doubling to $20.6B. The company significantly strengthened its balance sheet with stockholders' equity growing to $26.5B, while also increasing total debt to $29.5B to fund expansion. Operating cash flow generation was notably higher at $16.8B, supporting increased share buybacks of $4.1B and substantial inventory builds that position the company for continued growth.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+94.9%
$10.6B→$20.6B

Net income grew 94.9% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+90.7%
$8.8B→$16.8B

Operating cash flow surged 90.7% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
+87%
$14.2B→$26.5B

Equity base grew 87% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Inventory
Balance Sheet
+81.1%
$7.6B→$13.7B

Inventory surged 81.1% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+69.9%
$32.7B→$55.6B

Current assets grew 69.9% — improving short-term liquidity or inventory/receivables build.

Share Buybacks
Cash Flow
+64.3%
$2.5B→$4.1B

Share repurchases increased 64.3% — management returning capital, signals confidence in intrinsic value.

Accounts Receivable
Balance Sheet
+61.4%
$11.0B→$17.8B

Receivables surged 61.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Debt
Balance Sheet
+54.3%
$19.1B→$29.5B

Debt increased 54.3% — substantial leverage increase; assess whether deployed for growth or covering losses.

Interest Expense
P&L
+46.5%
$331.6M→$485.9M

Interest expense surged 46.5% — significant debt increase or rising rates materially impacting earnings.

Revenue
P&L
+44.7%
$45.0B→$65.2B

Strong top-line growth of 44.7% — accelerating demand or successful expansion into new markets.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-19
ADDED
Management's Discussion and Analysis of Results of Operations and Financial Condition 43 Item 7A.
Inluriyo For the treatment of adults with ER-positive HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy.
Jaypirca For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor; and for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
The products we market and their distribution vary from country to country depending on the market and applicable regulations.
As applicable, we educate healthcare providers about our products in various ways, including via promotion in online and other channels, distributing information and samples of certain products to physicians, and exhibiting at medical meetings.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Results of Operations and Financial Condition 41 Item 7A.
Jaypirca For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor; and for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
We educate healthcare providers about our products in various ways, including promoting in online channels, distributing literature and samples of certain products to physicians, and exhibiting at medical meetings.
Our account managers service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies.
We enter into arrangements with these organizations to provide discounts or rebates on our products.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →